SGLT2 Inhibitors vs GLP-1 Receptor Agonists: What Cardiovascular Evidence Shows
Episode Summary
A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and empagliflozin’s arrhythmia signal requires confirmation.